Abstract
Objective: To explore the curative effect and influence on glucose and lipid metabolism of risperidone with Shu Mian capsules in patients with schizophrenia . Methods: 128patients with chronic schizophrenia were randomly divided into the combined group (crisperidone combined with shu mian capsules group) and the single group (risperidone group ), each group was assessed the positive and negative syndrome scale (PANSS),the body mass index (BMI ) was measured and the blood glucose and blood lipid were detected before treatment and after 2,4,8 weekends respectively. After 4,8 weeks ,both the two groups were assessed by Wesconsin card sorting test ( WCST) curative effect and their cognitive function was evaluated . Results: The reacting time in the two groups were of no significantly difference , but compared with condition before treatment, cognitive function of the patients with schizophrenia was improved and their level of total cholesterol was significantly increased ( P < 0.05) in the combined group. BMI, blood glucose and blood lipid were significantly increased in single group after 8weeks’ treatment ( P < 0.05 or P < 0.01). Conclusion: Shu Mian capsules can lower negative symptoms and improve cognitive function of schizophrenia ,and the dverse reactions is mild. With therapeutic dose range, risperidone in combined group or single group can make equal reacting time, curative effect and affecting blood lipid metabolism in patients with schizophrenia. Single group shows more obvious influence on blood sugat and blood fat metabolismcan.
Highlights
[2] Cho SJ,Yook K, Kim B, et al Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizo -phrenia patients treated with risperidone: A randomized controlled trial [J]
[7] Liu EJ, Zhang W, Bai YP,et al Observation on clinical efficacy of depression treated with the alliance of acupuncture and medication [J]
Pentobarbital induced sleep may be related to postsynaptic 5-HT(1A) receptors[J]
Summary
Chronic schizophrenia; Risperidone; Shu Mian capsules; Cognitive function; Negative symptoms; Blood glucose; Blood lipid. 【摘要】目的 探讨利培酮合并舒眠胶囊治疗慢性精神分裂症的疗效及对患者糖、脂代谢的影响。方法 128 例精神分裂症 患者采用系统随机分为联合组(利培酮合并舒眠胶囊组)和单用组(利培酮组)。每组各 64 例分别于治疗前及治疗 2、4、8 周末采用阳性与阴性症状量表(PANSS)进行评分,并检测体质量指数(BMI)、血糖及血脂;4、8 周末评价认知能力及疗 效。结果 联合组和单用组起效时间比较差异无统计学意义;联合组能部分改善精神分裂症患者的认知能力,与治疗前相比 8 周未联合组总胆固醇明显增高(P
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
